Life Sciences Partnering 2025

4–5 Jun 2025 | Innsbruck, Austria

Register
Register
Register

Verena Biedermann-Dreiseitl

R&D Funding Expert, Senior Consultant

Cemit GmbH

Innsbruck, Austria

2 profile visits

I have many years of experience in applying for R&D funding and realising regional, national and transnational R&D individual and cooperation projects.

My organisation

Cemit GmbH

Cemit GmbH

Company

Innsbruck, Austria

Cemit GmbH in Innsbruck is a service company and has been active in the field of R&D funding and innovation consulting as well as project management for many years. As a result, Cemit GmbH has extensive experience in the application and management of regional, national and EU-wide funding projects, including access to a Europe-wide network of funding bodies and project partners.
Read more

About me

I am a senior consultant and project manager at the Cemit GmbH in Innsbruck, Austria since 2015. I studied chemistry at the Leopold-Franzens-University of Innsbruck for two years and then proceeded with microbiology. After a stay abroad at the Dana Farber Cancer Institute, Harvard Medical School, Boston I received my Ph.D. in molecular biology in 2000. In my professional career I worked as a medical consultant, information specialist, clinical research associate and lecturer. In my position as a clinical research associate at the Medical University of Innsbruck I acted as a consultant to the scientific personnel about the (legal) requirements for conducting clinical trials in Austria, prepared relevant study documents and accompanied the submission to legal authorities and the conducting of clinical trials. Furthermore, I held lectures about diverse aspects of clinical trials with medicinal products and medical devices including data protection requirements and preclinical development at the Medical University of Innsbruck and the Management Center Innsbruck. My current work at the Cemit GmbH involves R&D project development, funding application and project management with a focus on Life Sciences, MedTech and ICT.